Temporal profile of body temperature in acute ischemic stroke: relation to stroke severity and outcome
© Karaszewski et al.; licensee BioMed Central Ltd. 2012
Received: 21 April 2012
Accepted: 11 October 2012
Published: 18 October 2012
Pyrexia after stroke (temperature ≥37.5°C) is associated with poor prognosis, but information on timing of body temperature changes and relationship to stroke severity and subtypes varies.
We recruited patients with acute ischemic stroke, measured stroke severity, stroke subtype and recorded four-hourly tympanic (body) temperature readings from admission to 120 hours after stroke. We sought causes of pyrexia and measured functional outcome at 90 days. We systematically summarised all relevant previous studies.
Amongst 44 patients (21 males, mean age 72 years SD 11) with median National Institute of Health Stroke Score (NIHSS) 7 (range 0–28), 14 had total anterior circulation strokes (TACS). On admission all patients, both TACS and non-TACS, were normothermic (median 36.3°C vs 36.5°C, p=0.382 respectively) at median 4 hours (interquartile range, IQR, 2–8) after stroke; admission temperature and NIHSS were not associated (r2=0.0, p=0.353). Peak temperature, occurring at 35.5 (IQR 19.0 to 53.8) hours after stroke, was higher in TACS (37.7°C) than non-TACS (37.1°C, p<0.001) and was associated with admission NIHSS (r2=0.20, p=0.002). Poor outcome (modified Rankin Scale ≥3) at 90 days was associated with higher admission (36.6°C vs. 36.2°C p=0.031) and peak (37.4°C vs. 37.0°C, p=0.016) temperatures. Sixteen (36%) patients became pyrexial, in seven (44%) of whom we found no cause other than the stroke.
Normothermia is usual within the first 4 hours of stroke. Peak temperature occurs at 1.5 to 2 days after stroke, and is related to stroke severity/subtype and more closely associated with poor outcome than admission temperature. Temperature-outcome associations after stroke are complex, but normothermia on admission should not preclude randomisation of patients into trials of therapeutic hypothermia.
KeywordsIschemic stroke Tympanic body temperature Pyrexia Outcome OCSP
Previous studies of body temperature and outcome after stroke - methods
First author and year
Types of stroke
Temperature measurement method
Time of 1st; interval; last reading
Definition of pyrexia
Any stroke <48 hrs (not SAH)
N/S; 12 h; 7 d
Max temp in 7 d, logistic regression
CNS, serial GCS up to 30 d, 1, 3 & 6 month Barthel
≤37.2 = absence of fever. ≥37.9 = high fever
Any stroke <6 hrs
<6 h; -; -
Lesion size, SSS, presence of infection, WCC
<24 h; 2 h; 72 h
Correlate peak temp with clinical outcome and final infarct vol. Stepwise logistic regression
CSS, presence of infection, 4–7 d lesion volume, 3 month Barthel
Most A, some RC
<48 h; 3 h; -
Presence/absence of fever and infection. Stepwise logistic regression
GCS, SSS, CT lesion volume, presence of infection, use of invasive procedures
>37.5 on >2 occasions on 2 consec. days
Any “acute” stroke
“Admission” but no time limit given; -; -
Logistic regression. ischaemic vs. haemorrhagic stroke
Co-morbidities, WCC, [glucose], mortality (in-hospital and 1 yr)
<6 h; 2–4 h; 48 h
Mean temp analysis by subgroup
SSS, 3 month mRS
<6 h; -; -
Dichotomised normothermia vs. pyrexia, and multivariate survival analysis
SSS, [glucose], 5 yr mortality
Ischaemic; Excl pts with infection pre- or post- stroke
O or RC
<24 h (mean 6.7 h); 2–12 h; 3 d
Subgroup analysis of median temp days 1-3
NIHSS, WCC, CRP, 1–5 d lesion volume (CT/MR)
Ischaemic; Excl pts on antibiotics on admission
<12 h; continuous; 48 h
Dichotomised according to hyperthermia or not within 48 h
baseline NIHSS, presence of infection, effect of antipyretics
Ischaemic, with thrombo-lysis
<180 mins; random; 24 h;
AUC relative to 37° and to baseline T°
NIHSS, 3 month mRS
First ischaemic; Excl pts with inflammatory or infectious disease
<24 h; -; -
Presence vs. absence baseline pyrexia
CSS, BP, blood biochemistry, 4–7 d lesion volume (CT)
<48 h (median 2.5 h); 4 h; 48 h
Mixed model, Lowess curves
Baseline NIHSS, use of paracetamol, presence of infection
Ischaemic with thrombo-lysis
<3 h; random; 5 d
Pre-thombolysis temperature and peak temperature in 5 d
NIHSS, 3 month mRS, BP, peak [glucose]
Ischaemic stroke with thrombolysis
<3 h; 6 h; 48 h
Pre-thrombolysis, temperature at 24 and 48 h, and peak temperature within 24 h post- thrombolysis
NIHSS, 3 month mRS, early lesion vol (CT), MCA TIBI score (TCD)
Most patients: A; others N/S
N/S; 8 then 24 hrly; 7 d
Normotherm vs. pyrexia at different time points
WCC, NIHSS, 3 month mRS, lesion vol (1–7 d CT/MR), use of antibiotics
Any stroke <12 hrs
T or RC
median 6 h, all <12 h; -; -
Multiple logistic regression
baseline NIHSS, 14 d Barthel, 3 month mRS
250 (111 vs. 139)
< 6 h; -; -
Logistic regression, temperature against outcome in tPA-treated vs. non-treated patients
baseline NIHSS, mRS on day 7 or at discharge, vascular risk factors, stroke aetiology
Ischaemic, NIHSS ≥ 2
Majority – T, partially unknown
<48 h; -; -
vascular risk factors, NIHSS, stroke aetiology
Previous studies of body temperature and outcome after stoke – key results
First author and year
High fever (≥37.9°C) <7 d is independent risk factor for poor prognosis. Fever occurred in 43% of stroke pts <7 d. Onset of fever occurred in first 2 days in 64% of febrile patients.
Admission body temp is independently related to stroke severity, lesion size, mortality and outcome. [unclear how measured “outcome”; didn’t separate AIS from ICH]
The relationship between the degree of hyperthermia and stroke outcome/FIV is strongest when it begins within 24 h of symptom onset.
Fever in stroke is assoc with ↑age, ↑severity, more invasive techniques, worse outcome. When fever present without focus of infection, it tends to occur earlier.
For ischaemic stroke, admission temp (time unspecified) was significant predictor of in-hospital mortality: for each 1° increase, OR ↑ by 3.9 (CI 1.9 to 7.8, p<0.001).
Temp < 6 h post stroke onset has no prognostic influence on 3 month mRS. More severe strokes have higher temperature in first 48 h. [Also looked at ICH]. 7 d fatality rate higher in patients with lower body temp on admission.
For all strokes, a 1° difference in admission body temperature gives 30% increase in relative risk of 5 yr mortality. No association between admission temp and survival in pts still alive at 3 months.
Larger stroke volume and greater NIHSS assoc with higher temp, CRP and WCC. Successful thrombolysis attenuates inflammatory response
56% developed hyperthermia in 1st 48 h. Infectious cause found in 1/3 of patients.
Hyperthermia relative to baseline in 24 h (post rtPA) is assoc with unfavourable outcome
Hyperthermia assoc with higher levels of proinflammatory markers. Inflammatory mediators play a role in acute ischaemic brain damage independently of hyperthermia
Mean temp rise in first 24 h from 36.5 to 36.7°, peak at 36 h. More severe strokes have higher temp rise.
Body temp before thrombolysis was not assoc with 3 month outcome, but high temp thereafter was.
Body temp ≥37 at 24 h but not at baseline was assoc with lack of recanalisation, greater hyperdensity volume and worse functional outcome, regardless of stroke severity and time to treatment
Hyperthermia assoc with poor outcome. Delayed hyperthermia is more strongly assoc with poor outcomes than early hyperthermia. No association between baseline hyperthermia and outcome.
Baseline body temp was not related to improvement. Increased body temp at 24 h was associated with low likelihood of improvement.
High body temperature was associated with favorable short-term outcome in those who were thrombolysed vs. those not thrombolysed
High “fever burden” (combination of fever height and duration) was associated with death or with referral to hospice
We obtained measurements of body temperature every four hours from admission to five days after acute ischemic stroke as part of a study to examine serial changes in the ischaemic lesion on MR imaging. We used these data to clarify the temporal profile, associations with stroke severity, subtype and functional outcome and proportion with an alternative explanation for pyrexia.
We prospectively recruited patients >18 years old who presented with potentially disabling ischemic stroke. We excluded patients with intracerebral haemorrhage (ICH), coma, serious intercurrent illness, and technical or clinical incompatibility with MR scanning. Ethical approval was granted by the Scottish Multi-Centre Research Ethics Committee (06/MRE00/119) and we obtained informed, written consent from all patients or their relatives.
At admission, we recorded National Institute of Health Stroke Score (NIHSS) and the Oxford Community Stroke Project (OCSP) stroke subtype classification . All patients underwent MR imaging to diagnose the ischemic stroke. We recorded temperature using a First Temp Genius® tympanic thermometer immediately on arrival at hospital, and four hourly thereafter up to 120 hours. Recordings were taken from the uppermost ear in most patients, and from both ears in 11 patients to test side-to-side variation . Tympanic thermometry is considered reliable for serial readings , shows the least variation with age compared with axillary, rectal and oral thermometry , and is widely used in clinical practice. Pyrexia was defined as temperature ≥37.5°C . We searched for causes of pyrexia by collecting data on evidence of infection (evident infectious agent, leukocytes in body fluid, signs on imaging), DVT and surgical intervention as well as paracetamol and antibiotic use. Our policy is to prescribe paracetamol to patients who develop pyrexia (or for other indications such as pain relief) and antibiotics when positive evidence of infection and an infectious agent is diagnosed. We recorded modified Rankin Scale score (mRS) at three months after stroke, blind to temperature measurements.
We compared admission, peak and final temperatures and calculated area under the temperature/time curve (AUC) which we standardised (AUC[s]) by assuming all patients had a temperature of 36.5°C between stroke and the admission recording, and dividing AUC by the time of final temperature reading . We tested the association between temperature profile and measures of stroke severity firstly as determined by NIHSS, secondly by comparing total anterior circulation strokes (TACS) vs. less severe stroke subtypes (non-TACS) and thirdly good (mRS ≤2) vs. poor (mRS≥3) 90 day outcome. We adjusted analysis for age and admission NIHSS where appropriate. We used Student’s t-test for parametric and Mann Whitney U tests and Spearman correlation for non-parametric data.
Baseline data, pyrogenic factors and use of antibiotics and thrombolysis
No pyrexia n=28
Mean Age in years, (SD)
Median NIHSS (IQR)
Time to peak, median hours after stroke, (IQR)
N o . with ≥1 pyrogenic factor identified*
90 day mRS
There was no difference between ipsi- and contralateral tympanic temperature readings obtained simultaneously (36.6°C vs 36.6°C, 95% confidence interval (CI) -0.19 to 0.16, p=0.821) in 11 patients (five TACS). The mean number of temperature readings per patient was 14 (SD 6.9). No patients died during the observation period.
When temperature was first measured on admission, at a median 4 (interquartile range (IQR) 2 to 7.8) hours after stroke, all patients were normothermic (mean 36.4°C, 95% CI 36.2 to 36.6) (Table 3). Peak temperature (mean 37.3°C, 95% CI 37.1 to 37.5) occurred at median 35.5 hours (IQR 19.0-53.8) after stroke. The latest temperature (mean 36.5°C, 95% CI 36.3 to 36.7) was recorded at median 108.5 hours (IQR 98.8-113.5) after stroke.
Admission NIHSS score was not associated with admission temperature (adjusted r2=0.0, p=0.353), but was associated with peak (adjusted r2=0.20, p=0.002), and final (adjusted r2=0.25, p=0.001) temperatures. NIHSS was also associated with the overall temperature profile AUC[s] (adjusted r2=0.07, p=0.047).
Mean admission, peak and final body temperatures in patients grouped according to OCSP classification
Stroke subtype (OCSP)
Admission temperature °C (95% CI)
Peak temperature °C (95% CI)
Final temperature °C (95% CI)
90 day mRS 0 to 2 (n)
90 day mRS 3 to 6 (n)
Sixteen (36%) patients became pyrexial (at least one temperature reading of ≥37.5°C) during the recording period: 9/14 (64%) TACS patients and 7/30 (23%) non-TACS (χ2=6.9, p=0.009). Of the 16 pyrexial patients, at least one potential cause of pyrexia was identified in nine (56%), but 11/16 (69%) had no infection and 7/16 (44%) had no identified cause for pyrexia (apart from the stroke). Conversely, a potential pyrogenic factor was identified in 7/28 (25%) patients without pyrexia (Table 3). Thirteen patients were prescribed paracetamol of whom seven were recorded as having pyrexia and six were not (OR for pyrexia associated with paracetamol=1.8, 95% CI 0.48 to 6.77). The reason for paracetamol administration in the patients without pyrexia was mostly for pain relief. Ten patients with poor outcome (40%) had been prescribed paracetamol but only in three (16%) patients with good outcome (OR for poor outcome 3.56, 95% CI 0.82 to 15.46).
In patients with ischemic stroke, tympanic temperature was not elevated on admission even in patients with more severe strokes (TACS), and admission temperature did not correlate with admission NIHSS. Instead, we found that peak temperature, occurring at around 1.5 to 2 days after stroke and overall temperature, as expressed by AUC were associated with admission stroke severity as measured by NIHSS and TACS subtype. Peak temperatures were higher, occurred later and temperature elevation lasted longer in more severe than less severe strokes perhaps indicating a more prolonged, greater inflammatory response to the volume of infarcted tissue. Patients with poor functional outcome (mRS≥3) at 90 days had higher admission and peak temperatures than patients with good outcome (mRS≤2), although all admission temperatures were <37°C. We were not able to find a source of infection in 69% of pyrexial patients, and no alternative cause of pyrexia, other than the stroke itself, in 44%.
This prospective study of detailed four-hourly tympanic temperature measurements up to five days after ischemic stroke helps explain the varying results of previous studies (Tables 1 and 2) some of which found associations between admission temperature, stroke severity and outcome [3, 4, 6, 12, 13], while others did not [8, 14, 16, 19]. This variation can be attributed to some studies being retrospective, or not specifying the timing of temperature recording after stroke, sampling temperature only once, measuring “admission” temperature relatively late after stroke, only measuring serial temperature up to 72 hours, the different severities of stroke included in each study or including patients with both haemorrhagic and ischemic stroke. Consistent with our results, others showed that patients with more severe strokes experience higher peak temperatures , and that elevated temperature at 24 hours [14, 17, 19], 48 hours  or 7 days  after stroke was more closely linked to poor outcome than admission readings. Our detailed longitudinal findings also demonstrate the higher, later and longer duration of temperature elevation in more severe than less severe stroke, which perhaps has not been appreciated previously.
Our study has limitations. The small sample size was constrained by selection of patients for an MR imaging study, but on the other hand it allowed very detailed temperature monitoring. However, the range of stroke severity was consistent with those that would be considered for trials of therapeutic hypothermia. A larger sample size would allow more adjustment for potential confounders, and clarification of the significance of any differences in timing of peak temperature readings, and comparison of patients whose tympanic temperature may have been affected by antibiotics and antipyretics, although our results show that pyrexia was just as common in patients who were prescribed paracetamol as in those who were not, in contrast to others’ results . However paracetamol may have influenced the profile of temperature change. Although our data on temperature profile and stroke severity are consistent with five previous studies, we cannot exclude the possibility of an association between admission temperature and stroke severity. The study strengths are the detailed four-hourly tympanic temperature measurements for 120 hours after ischemic stroke and the detailed comparison with stroke subtype, severity and outcome. The duration of temperature recording ensured that the peak temperature was captured in both TACS and non-TACS.
Two other points raise questions for further study. Admission temperature in the patients with more severe strokes, ie TACS, was not higher than in patients with milder strokes, as might have been expected. Perhaps, by analogy with other serious acute illness, the temperature in severe stroke may reflect severe illness . Secondly, why do patients with a poor outcome have a marginally higher (but still normothermic) admission temperature, and while severe stroke is associated with poor outcome, severe stroke is not associated with admission temperature? This might be explained at least in part by a possible cascade of events suggested in experimental data. Increased temperature opens the blood–brain barrier  which, in acute ischemia, would lead to increased extracellular oedema, more infarct swelling, more restricted capillary flow in the ischemic tissue, less chance of reperfusion, all contributing to increasing ischemic damage, swelling and leading to a larger infarct around 48 hours , consolidating the potential for tissue damage that was suggested by the severe stroke symptoms at presentation, and consequently leading to the poor outcome at 90 days. Longer duration of temperature monitoring should be considered in future research to improve understanding of temperature profiles after stroke.
This interpretation, if true, raises some implications for therapeutic hypothermia trials. Firstly, and paradoxically, patients may benefit the most from hypothermia if it prevents the tissue cascade outlined above from causing more tissue damage and should certainly not be excluded from trials; thus cooling should be initiated as early as possible and not influenced by the patient’s admission temperature. However cooling may only prevent worsening of damage, not actively salvage tissue that is already at risk, so combinations of therapies to salvage (e.g. thrombolysis) as well as to restrict progressive new damage (e.g. hypothermia, if it works) may be required. Secondly, if the main effect of hypothermia is to reduce blood–brain barrier opening thus preventing the cascade that leads to larger stroke lesions, then hypothermia could still be valuable if started many hours after the stroke when the possibility of salvaging at risk tissue was lost but there was still some “future secondary damage” to prevent. If correct, then hypothermia should reduce subacute infarct oedema and mass effect. Thirdly, if correct, then therapeutic thrombolysis and hypothermia should work synergistically to produce greater benefit than either alone. However hypothermia may also have some disadvantages. In addition to increased risk of secondary infection and the need to manage unpleasant side effects like shivering, lower temperatures might delay thrombus lysis which pyrexia might accelerate. The balance of risk and benefit presented by these possibilities requires testing in future therapeutic trials of hypothermia after stroke.
The association between body temperature, stroke severity and functional outcome is complex and, if our observations in this small detailed study are verified, then even very marginal differences in admission temperature in normothermic patients may provide a mechanism whereby, for a given stroke severity, potential tissue damage is converted into more severe damage resulting in a poor outcome, which might be prevented by therapeutic hypothermia.
We thank the UK Stroke Research Network nurses who performed the serial temperature measurements. RGT was funded by The Stroke Association (Registered Charity SC037789), Project Ref No: TSA 2006/11, BK by the Foundation for Polish Science and the International Brain Research Organization (IBRO), JMW by the Scottish Funding Council SINAPSE Collaboration (http://www.sinapse.ac.uk).
- Sulter G, Elting JW, Maurits N, Luijckx GJ, De KJ: Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. Cerebrovasc Dis. 2004, 17: 118-122. 10.1159/000075779.View ArticlePubMedGoogle Scholar
- Azzimondi G, Bassein L, Nonino F, Fiorani L, Vignatelli L, Re G, D’Alessandro R: Fever in acute stroke worsens prognosis. A prospective study. Stroke. 1995, 26: 2040-2043. 10.1161/01.STR.26.11.2040.View ArticlePubMedGoogle Scholar
- Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, Olsen TS: Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996, 347: 422-425. 10.1016/S0140-6736(96)90008-2.View ArticlePubMedGoogle Scholar
- Georgilis K, Plomaritoglou A, Dafni U, Bassiakos Y, Vemmos K: Aetiology of fever in patients with acute stroke. J Int Med. 1999, 246: 203-209. 10.1046/j.1365-2796.1999.00539.x.View ArticleGoogle Scholar
- Hajat C, Hajat S, Sharma P: Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke. 2000, 31: 410-414. 10.1161/01.STR.31.2.410.View ArticlePubMedGoogle Scholar
- Kammersgaard LP, Jorgensen HS, Rungby JA, Reith J, Nakayama H, Weber UJ, Houth J, Olsen TS: Admission body temperature predicts long-term mortality after acute stroke: the Copenhagen Stroke Study. Stroke. 2002, 33: 1759-1762. 10.1161/01.STR.0000019910.90280.F1.View ArticlePubMedGoogle Scholar
- Saini M, Saqqur M, Kamruzzaman A, Lees KR, Shuaib A, on behalf of the VISTA Investigators: Effect of hyperthermia on prognosis after acute ischemic stroke. Stroke. 2009, 40: 3051-3059. 10.1161/STROKEAHA.109.556134.View ArticlePubMedGoogle Scholar
- Boysen G, Christensen H: Stroke severity determines body temperature in acute stroke. Stroke. 2001, 32: 413-417. 10.1161/01.STR.32.2.413.View ArticlePubMedGoogle Scholar
- Castillo J, Davalos A, Marrugat J, Noya M: Timing for fever-related brain damage in acute ischemic stroke. Stroke. 1998, 29: 2455-2460. 10.1161/01.STR.29.12.2455.View ArticlePubMedGoogle Scholar
- Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC: Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke. 2008, 39: 3029-3035. 10.1161/STROKEAHA.108.521583.View ArticlePubMedGoogle Scholar
- Leira R, Rodriguez-Yanez M, Castellanos M, Blanco M, Nombela F, Sobrino T, Lizasoain I, Davalos A, Castillo J: Hyperthermia is a surrogate marker of inflammation-mediated cause of brain damage in acute ischaemic stroke. J Int Med. 2006, 260: 343-349. 10.1111/j.1365-2796.2006.01694.x.View ArticleGoogle Scholar
- Wang Y, Lim LL, Levi C, Heller RF, Fisher J: Influence of admission body temperature on stroke mortality. Stroke. 2000, 31: 404-409. 10.1161/01.STR.31.2.404.View ArticlePubMedGoogle Scholar
- Audebert HJ, Rott MM, Eck T, Haberl RL: Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke. 2004, 35: 2128-2133. 10.1161/01.STR.0000137607.61697.77.View ArticlePubMedGoogle Scholar
- Ernon L, Schrooten M, Thijs V: Body temperature and outcome after stroke thrombolysis. Acta Neurol Scand. 2006, 114: 23-28. 10.1111/j.1600-0404.2006.00596.x.View ArticlePubMedGoogle Scholar
- Wong AA, Davis JP, Schluter PJ, Henderson RD, O’Sullivan JD, Read SJ: The time course and determinants of temperature within the first 48 h after ischaemic stroke. Cerebrovasc Dis. 2007, 24: 104-110. 10.1159/000103124.View ArticlePubMedGoogle Scholar
- Idicula TT, Waje-Andreassen U, Brogger J, Naess H, Lundstadsveen MT, Thomassen L: The effect of physiologic derangement in patients with stroke treated with thrombolysis. J Stroke Cerebrovasc Dis. 2008, 17: 141-146. 10.1016/j.jstrokecerebrovasdis.2008.01.010.View ArticlePubMedGoogle Scholar
- Millan M, Grau L, Castellanos M, Rodriguez-Yanez M, Arenillas JF, Nombela F, Perez De La Ossa N, Lopez-Manzanares L, Serena J, Castillo J, Davalos A: Body temperature and response to thrombolytic therapy in acute ischaemic stroke. Eur J Neurol. 2008, 15: 1384-1389. 10.1111/j.1468-1331.2008.02321.x.View ArticlePubMedGoogle Scholar
- den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ, Dippel DW: An early rise in body temperature is related to unfavorable outcome after stroke: data from the PAIS study. J Neurol. 2011, 258: 302-307. 10.1007/s00415-010-5756-4.View ArticlePubMedGoogle Scholar
- Den Hertog HM, Van der Worp HB, Van Gemert HM, Algra A, Kappelle LJ, Van Gijn J, Koudstaal PJ, Dippel DW, PAIS Investigators: The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol. 2009, 8: 434-440. 10.1016/S1474-4422(09)70051-1.View ArticlePubMedGoogle Scholar
- Naess H, Idicula T, Lagallo N, Brogger J, Waje-Andreassen U, Thomassen L: Inverse relationship of baseline body temperature and outcome between ischemic stroke patients treated and not treated with thrombolysis: the Bergen stroke study. Acta Neurol Scand. 2010, 122: 414-417.View ArticlePubMedGoogle Scholar
- Phipps MS, Desai RA, Wira C, Bravata DM: Epidemiology and outcomes of fever burden among patients with acute ischemic stroke. Stroke. 2011, 42: 3357-3362. 10.1161/STROKEAHA.111.621425.View ArticlePubMedGoogle Scholar
- Leira R, Sobrino T, Blanco M, Campos F, Rodríguez-Yáñez M, Castellanos M, Moldes O, Millán M, Dávalos A, Castillo J: A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA). Clin Sci (Lond). 2012, 122: 113-119. 10.1042/CS20110143.View ArticleGoogle Scholar
- Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991, 337: 1521-1526. 10.1016/0140-6736(91)93206-O.View ArticlePubMedGoogle Scholar
- Rampen AJ, van Breda EJ, Dippel DW: Tympanic measurement of body temperature in stroke patients “turned on its ear”. J Neurol Neurosurg Psychiatry. 2005, 76: 1041-1042.View ArticlePubMedPubMed CentralGoogle Scholar
- Togawa T: Body temperature measurement. Clin Phys Physiol Meas. 1985, 6: 83-108. 10.1088/0143-0815/6/2/001.View ArticlePubMedGoogle Scholar
- Lu SH, Leasure AR, Dai YT: A systematic review of body temperature variations in older people. J Clin Nurs. 2009, 19: 14-16.Google Scholar
- Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ. 1990, 300: 230-235. 10.1136/bmj.300.6719.230.View ArticlePubMedPubMed CentralGoogle Scholar
- Kiyatkin EA, Sharma HS: Permeability of the blood–brain barrier depends on brain temperature. Neuroscience. 2009, 161: 926-939. 10.1016/j.neuroscience.2009.04.004.View ArticlePubMedPubMed CentralGoogle Scholar
- Wardlaw JM, Dennis MS, Lindley RI, Warlow CP, Sandercock PAG, Sellar R: Does early reperfusion of a cerebral infarct influence cerebral infarct swelling in the acute stage or the final clinical outcome?. Cerebrovasc Dis. 1993, 3: 86-93. 10.1159/000108678.View ArticleGoogle Scholar
- Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003, 31: 1250-1256. 10.1097/01.CCM.0000050454.01978.3B.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/12/123/prepub